

ECPP is a London based international HIV/AIDS and Hepatitis C patient organisation working in Europe and Malawi, promoting patient involvement in the development of public policy, delivery and monitoring of services.
Mission
To become a European1 organisation of positive people which will advocate and campaign for our human and civil rights, offer peer support, challenge misinformation and prejudice, while galvanising the diverse, affected communities into action, ensuring access to effective treatments, services and promoting healthy living.
1 Defined in this instance to include the member states of the EU, applicant states and Eastern Europe.
Values
Our ethos is one of self-help. We believe that people living with and/or affected by HIV, Hepatitis C and Tuberculosis should be central to the relevant debates about health and social policy. People have the right to information, backup and role models, and can then deal effectively with the world on their own or with each other's support.
The organisation must be run by, controlled by and represented by a majority of positive people. All member organisations must be as well.
Aims & Objectives
Issues of concern
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close